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Background: The prevalence of long-term opiate use in treating chronic non-cancer pain is increasing, and
prescription opioid abuse and dependence are a major public health concern. To explore alternatives to
opioid-based analgesia, the present study investigates a novel allosteric pharmacological approach operating
through the cation channel TRPV1. This channel is highly expressed in subpopulations of primary afferent
unmyelinated C- and lightly-myelinated Aδ-fibers that detect low and high rates of noxious heating, respectively,
and it is also activated by vanilloid agonists and low pH. Sufficient doses of exogenous vanilloid agonists, such as
capsaicin or resiniferatoxin, can inactivate/deactivate primary afferent endings due to calcium overload, and we
hypothesized that positive allosteric modulation of agonist-activated TRPV1 could produce a selective, temporary
inactivation of nociceptive nerve terminals in vivo. We previously identified MRS1477, a 1,4-dihydropyridine that
potentiates vanilloid and pH activation of TRPV1 in vitro, but displays no detectable intrinsic agonist activity of its
own. To study the in vivo effects of MRS1477, we injected the hind paws of rats with a non-deactivating dose of
capsaicin, MRS1477, or the combination. An infrared diode laser was used to stimulate TRPV1-expressing nerve
terminals and the latency and intensity of paw withdrawal responses were recorded. qRT-PCR and
immunohistochemistry were performed on dorsal root ganglia to examine changes in gene expression and the
cellular specificity of such changes following treatment.
Results: Withdrawal responses of the capsaicin-only or MRS1477-only treated paws were not significantly different
from the untreated, contralateral paws. However, rats treated with the combination of capsaicin and MRS1477
exhibited increased withdrawal latency and decreased response intensity consistent with agonist potentiation and
inactivation or lesion of TRPV1-containing nerve terminals. The loss of nerve endings was manifested by an increase
in levels of axotomy markers assessed by qRT-PCR and colocalization of ATF3 in TRPV1+ cells visualized via
immunohistochemistry.
Conclusions: The present observations suggest a novel, non-narcotic, selective, long-lasting TRPV1-based approach
for analgesia that may be effective in acute, persistent, or chronic pain disorders.
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Adelta fiberBackground
During the past decade, the use of opiates for chronic
pain management has expanded from mainly postopera-
tive and oncological patients to include those with
chronic non-cancer pain. Consequently, the abuse of
and dependence on prescription opioids has become an
increasing public health concern [1-5]. Given the* Correspondence: miadarola@dir.nidcr.nih.gov
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reproduction in any medium, provided the ordetrimental side effects and addiction potential of these
medications, it is critical that we develop novel, non-
opiate based pharmacological agents to treat chronic
pain. One potential therapeutic avenue involves targeting
TRPV1, a sodium/calcium ion channel highly expressed
in a subpopulation of unmyelinated C- and lightly-
myelinated Aδ-afferent primary afferent neurons [6-9].
This receptor responds to multifactorial inputs and is
activated by temperature >43°C [7], protons [7], exogen-
ous vanilloid ligands such as capsaicin and resinifera-
toxin (RTX) [7], endogenous vanilloids such as NADAl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ious fatty acids [13-15]. It is also sensitized by post-
translational modifications through the actions of algesic
molecules produced after tissue injury or during inflam-
mation [16-20], and the plasma membrane expression of
TRPV1 is greatly upregulated in small- to medium-
diameter sensory neurons during inflammation [21,22].
Extensive drug development has been directed at gener-
ating antagonists of the TRPV1 orthosteric capsaicin-
binding site for acute and chronic pain. This research
yielded many outstanding pharmacological agents in sev-
eral chemical classes [23] that include, for example,
ABT-102 [24], SB-705498 [25], AS1928370 [26], and
AMG8562 [27]. However, as a class, this group of
antagonists encountered difficulties in transitioning to
clinical utilization due to two main side effects. The first
is an unpredictable level of hyperthermia; the propensity
for which is variable among individual agents [28]. The
second is that TRPV1 antagonists potently block hot
temperature sensation throughout the body and the loss
of cutaneous sensation to noxious thermal stimuli can
place these patients at risk for accidental burn injuries
[28].
In an attempt to circumvent some of the issues with
current TRPV1 antagonists, novel reversible or perma-
nent interventional neuroablative therapies based on
TRPV1 agonists are being explored [29,30]. Administra-
tion of a vanilloid agonist, such as capsaicin or its ultra-
potent analog RTX [31], can cause calcium-induced
cytotoxicity and lead to a TRPV1-selective axonopathy
that spares surrounding non-TRPV1-expressing somato-
sensory proprioceptive afferent and motor efferent nerve
fibers. The potency and selectivity of vanilloid agonists
for TRPV1 afferents has been demonstrated repeatedly
in vivo [8,32-40]. For example, ablation of TRPV1+ nerve
terminals occurring after a single subcutaneous injection
of RTX into the rat hind paw results in prolonged but
reversible analgesia that can be detected for one to sev-
eral weeks and induces up-regulation of molecular mar-
kers for axon damage/repair in neuronal perikarya of the
dorsal root ganglia [8,32]. We have also found that topi-
cal application of RTX onto the cornea results in tem-
porary loss of the capsaicin eyewipe response in parallel
with a loss of CGRP immunoreactive afferents in stro-
mal fiber bundles [41]. While the actions of peripherally
administered RTX are localized and reversible, RTX
given intrathecally produces a spatially broader effect
over multiple dermatomes with permanent pain relief
[33,34,36]. The therapeutic efficacy of intrathecal RTX is
especially evident in veterinary canine patients with
naturally-occurring osteosarcoma [34], and RTX deliv-
ered intrathecally to treat advanced cancer pain in
humans is currently in a Phase I clinical trial (<http://
clinicalstudies.info.nih.gov/detail/A_2009-D-0039.html>).At present, the only available FDA-approved agonist-
based treatments contain capsaicin in an over-the-
counter low dose (0.075%) topical cream and a high dose
(8%) prescription cutaneous patch [42]. Topical therapy
is reported to be effective for post-herpetic neuralgia
[35], HIV-associated distal sensory polyneuropathy [43],
and painful diabetic neuropathy [44]. Because TRPV1
agonists are painful initially upon application, in general,
administration of a TRPV1 agonist necessitates pretreat-
ment with a local anesthetic and, in the case of intrathe-
cal administration, general anesthesia, which requires
the patient to be either in the clinic or in the operating
room. In addition, while capsaicin is effective when
administered focally to treat Morton’s neuroma or
osteoarthritis [45] and RTX is effective when adminis-
tered intrathecally to treat osteosarcoma [34], they gen-
erally cannot be given systemically in large doses since
they produce a decrease in core body temperature and
may be cardiotoxic, although there is a much larger
safety margin for RTX [29]. Thus while some conditions
may be amenable to local, interventional TRPV1 agonist
administration, other pain conditions, where pain is
more diffuse or delocalized, may not be appropriate can-
didates for treatment with localized therapies.
TRPV1 is highly conductive, can integrate various
noxious stimuli, and is located in a clinically relevant
population of nociresponsive afferent neurons; these
characteristics make it an important therapeutic target.
In an effort to combine the ease of systemic administra-
tion of antagonists with the potent, long-lasting analge-
sic qualities of agonists, we are exploring positive
allosteric modulation of TRPV1 as a novel analgesic
mechanism [46]. An ideal TRPV1 positive allosteric
modulator (PAM) would have no intrinsic activity but
would enhance receptor activation by an orthosteric
agonist and, as a result, would act conditionally to
potentiate only TRPV1 on afferent nerves terminating in
regions of tissue damage or inflammation where chan-
nels are highly active (see Figure 1). By over-driving the
channel, a PAM acting directly on TRPV1 could induce
calcium-mediated toxicity in the active nerve terminals
or axons leading to functional inactivation or ablation
and ultimately to a focused, selective, long-lasting
analgesia. Here, we present in vivo evidence that it is
possible to positively modulate agonist-activated TRPV1-
expressing nerve terminals to the point of deafferenta-
tion. MRS1477, a small molecule 1,4-dihydropyridine
that we have previously identified [47] and characterized
[46] in vitro, was used to potentiate capsaicin-activated
nerve terminals in the rat hind paw. We examined
analgesic effects of terminal inactivation by measuring
acute thermal nociception and changes in gene expres-
sion markers of peripheral nerve terminal ablation,
damage, or axotomy in lumbar dorsal root ganglia. Our
Figure 1 Conceptualized model of PAM modulation directly on TRPV1. Homotetrameric TRPV1 is permeable to cations, notably sodium and
calcium, and possesses an orthosteric binding site for capsaicin and an allosteric binding site. At baseline, no agonist is bound and the channel is
closed (far left). Binding of a positive allosteric modulator does not activate channel opening (mid left). When an agonist such as capsaicin binds
(mid right), a conformational change allows sodium and calcium to flow into the neuron resulting in depolarization and, if threshold is reached,
generation of an action potential. When capsaicin binds, the allosteric site targeted by a PAM (far right) then becomes functionally accessible. The
PAM increases cation influx and the likelihood of axonal depolarization. Sufficient depolarization can result in calcium-induced cytotoxicity leading
to inactivation of the conductive potential of the axon and analgesia.
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TRPV1-expressing nerve terminals after a single, subcu-
taneous injection resulting in sustained analgesia lasting
several days. The present observations suggest a novel,
non-narcotic, selective, long-lasting TRPV1-based
approach for pain reduction that may be effective in
acute, persistent, or chronic pain disorders.
Methods
Animals
Male Sprague–Dawley rats (250–400g) were housed
under a 12h light–dark cycle and allowed access to food
and water ad libitum. The ambient temperature of the
holding and testing rooms was ~22°C. Procedures were
performed in accordance with the National Institutes of
Health (NIH) Guidelines for the Care and Use of
Laboratory Animals, and approved by the National Insti-
tute of Dental and Craniofacial Research (NIDCR) Ani-
mal Care and Use Committee. All efforts were made to
minimize both animal numbers and distress within the
experiments.
Drug solutions and administration
The drug vehicle for all experiments consisted of 7.5%
Tween-80 (Sigma-Aldrich, P8074) and 0.05% ascorbic
acid (Spectrum Chemical, AS105) in PBS, at pH 7.2.
Resiniferatoxin from stock (“RTX”, custom purification,
100 μg/ml in vehicle) was further diluted in vehicle to
200 ng/100 μl for injection. A 20 mM stock solution of
MRS1477 (FW=389.51, [47]) was prepared in 100%
DMSO (Sigma-Aldrich, D2650) and further diluted in
vehicle to either 1 μg/100 μl (25 μM) or 2 μg/100 μl (50μM), where specified. Capsaicin (“CAP”, Sigma-Aldrich,
M2028) was prepared as a 100 mM stock solution in
absolute ethanol, stored at −80°C, and was diluted
directly into vehicle on the day of the experiments to 30
μg/100 μl. CAP-only injectates contained an equal
amount of DMSO as those with MRS1477. All subcuta-
neous injections were made using a 29G×1/2", 3/10 cc
insulin syringe (Terumo Medical Corp., Cat No.
SS*30 M2913). The experimenter was blinded to the
identity of the injectates in the various behavioral
experiments.
Behavioral measurements
Behavioral assessments were performed as reported pre-
viously [8]. Briefly, unrestrained rats were placed on a
clear glass platform under a small plastic cage
(23×13×13 cm), which allowed them to move freely.
Groups of rats were habituated to the testing apparatus
for a minimum of three days by placing them under the
cages on the glass platform and given both Aδ- and C-
fiber laser stimuli. On the day of testing, rats were
allowed to habituate for at least 10 min prior to thermal
stimulation. Rats were tested prior to injection to estab-
lish a baseline, then at 2, 24, and 48 h post-injection. An
infrared diode laser (Lasmed LLC, Mountain View, CA)
was aimed at the ventral hind paw, with a perpendicular
approach to the plantar skin. Aδ-fibers were preferen-
tially stimulated with a short-pulse (100 msec) using a
high-intensity small-diameter (1.6 mm) beam, and beha-
vioral responses were assessed on a five-point scale:
0 = no response, 1 = orient to stimulus, 2 = orient with
paw lift, 3 = lift paw, orient, and shake, and 4 = lift paw
Lebovitz et al. Molecular Pain 2012, 8:70 Page 4 of 14
http://www.molecularpain.com/content/8/1/70with lick [8]. Only responses graded as 2 or above
included a paw withdrawal. Aδ-fibers were stimulated
with laser intensities ranging from 3.59 W/mm2 to
5.61 W/mm2. C-fibers were preferentially stimulated
with a continuous, wide-diameter (5 mm), low-energy
pulse (0.083 W/mm2) and paw withdrawal latency (sec)
served as the primary endpoint. One cohort of rats
(n = 4) receiving 2 μg MRS1477 + 30 μg CAP was tested
repeatedly for 24 days to evaluate the time course for
recovery of thermal sensitivity.
qRT-PCR analysis
Rats were euthanized 24 h post-injection. The L4, L5,
and L6 dorsal root ganglia were dissected and pooled as
either ipsilateral or contralateral to the drug injection
and then frozen on dry ice. Total RNA was extracted
using Qiazol (Qiagen, Cat No. 79306) and the RNeasy
Kit (Qiagen, Cat No. 74104) with a DNase I digestion
step, all according to the manufacturer’s instructions.
RNA integrity was verified using an Agilent 2100 Bioa-
nalyzer. All total RNA samples had an RNA integrity
number (RIN) between 8.3 and 9.5 with an average of
8.9. cDNA was synthesized from total RNA using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Cat No. 4368813) and Random Primers.
Quantitative Real-Time PCR (qRT-PCR) was performed
using Power SYBR Green Mastermix (Applied Biosys-
tems, Cat No. 4309155) on a Stratagene Mx3000P. Addi-
tionally, Reverse Transcription PCR (RT-PCR) was
performed using the Access RT-PCR system (Promega,
Cat No. A1250). RT-PCR products were resolved on a
2% agarose gel with ethidium bromide staining. All oli-
gonucleotide primer sequences are listed below (Table 1).
The results were normalized to GAPDH. Comparisons
of gene expression from ipsilateral vs. contralateral DRG
were made using a paired Student’s t-test. Markers of
axotomy included activating transcription factor 3Table 1 RT-PCR primer pairs and PCR product sizes












ACGGCCAAATCCGTTCACACC(“ATF3”; [48]), neuropeptide Y (“NPY”; [49]), galanin
(“GAL”; [50]), vasoactive intestinal polypeptide (“VIP”;
[51-53]), and monocyte chemoattractant protein 1
(“MCP-1”; [54]).
Statistical analyses
Comparisons of gene expression from ipsilateral and
contralateral tissues were made by paired Student’s t-
test. For other single comparisons between two different
groups, unpaired t-tests were used. For multiple compar-
isons, one-way and two-way ANOVA tests were used
with, respectively, Tukey’s post-hoc test and Bonferroni
multiple comparisons. For ordinal response score data
from behavioral ratings that were used to evaluate Aδ-
fiber responses, the Mann–Whitney U test was used.
Differences were considered significant where p < 0.05.
Time versus drug effects for longitudinal behavioral data
were analyzed using two-way ANOVA.
Immunohistochemistry
Rats used for immunohistochemistry were deeply
anesthetized with sodium pentobarbital and transcar-
dially perfused with cold PBS followed by 4% parafor-
maldehyde. The L4-L5-L6 dorsal root ganglia were
harvested bilaterally, post-fixed in 4% paraformaldehyde
for 2 h, cryopreserved in 20% sucrose, then mounted
and frozen for sectioning on a cryostat.
All DRG tissues were sectioned at 10 μm and mounted
directly onto slides and stored at −80°C until use. Prior
to staining with antibodies, the sections were thawed at
RT and allowed to air dry. The entire immunostaining
procedure was carried out at RT. Sections were washed
in HEPES Buffer (“HB”; see below) and fixed in 4% par-
aformaldehyde for 10 min, then washed in HB and
counterfixed in absolute methanol for 5 min. Antigen
retrieval was performed by incubation of sections in 1%
SDS for 5 min and the tissues were then incubated in
Background Buster solution (Innovex Biosciences, Cat
No. NB306-50) for 20 min to block non-specific anti-
body binding. Sections were subsequently washed in HB
and then incubated with primary antibodies of interest
(see below) diluted in HB for 1 h in a humidified cham-
ber. The unbound antibodies were washed away using
HB and the sections were then incubated with appropri-
ate fluorescently-labeled secondary antibodies (see
below) for 1 h in a dark, humidified chamber. Finally,
the sections were washed in HB to remove unbound
antibodies, sealed with Immuno Mount (GeneTex, Cat
No. GTX30928) and a coverslip, and were viewed the
following day.
All sections were imaged using a fluorescence micro-
scope (Axiovert 200 M; Carl Zeiss, Thornwood, NY)
equipped with a 20× Plan-Apochromat objective (Carl
Zeiss), a high-resolution cooled digital camera (ORCA-
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lamp light source and wavelengths selected with excita-
tion/dichroic/emission filter sets (Semrock, Rochester,
NY) optimized to detect the following fluorophores:
DAPI, Alexa Fluor 488, and Alexa Fluor 546. Each label-
ing reaction was captured using appropriate fluorescence
filter sets and the images individually digitized at 12-bit
resolution using the Volocity image acquisition program
(Improvision Inc., Lexington, MA). An appropriate color
table was applied to each image to either match its emis-
sion spectrum or to set a distinguishing color balance.
The pseudocolored images were then converted into
TIFF files, exported to Adobe Photoshop, and overlaid
as individual layers to display multi-colored merged
composites.
HEPES Buffer (HB)
HB was made fresh prior to staining and kept at 4°C.
Buffer was made in 1 liter batches and contained
145 mM NaCl, 5 mM KCl, 0.8 mM MgCl2, 1.8 mM
CaCl2, 10 mM HEPES, and 0.1% BSA. The solution was
filter sterilized and the pH was adjusted to 7.3 with
NaOH/HCl.
Antibodies
Polyclonal primary antibodies consisted of anti-TRPV1
(guinea pig, 1:100, Novus Biologicals, Cat No. NB300-
122) and anti-ATF3 (rabbit, 1:200, Santa Cruz Biotech-
nology, Cat No. sc-188). Both primary antibodies were
diluted with glycerol 1:1 prior to use to limit degradation
following repeated freeze-thaw cycles. Fluorescently
labeled secondary antibodies were purchased from Invi-
trogen and consisted of goat anti-guinea pig Alexa Fluor
488 (1:200, Cat No. A-11073) and goat anti-rabbit Alexa
Fluor 546 (1:200, Cat No. A-11035). All antibodies were
diluted from stock solutions to working concentrations
with HB.
Results
In order to evaluate the in vivo effects of MRS1477, we
measured nociceptive responses to thermal stimuli in
Aδ- and C-fibers after mid-plantar injections into rat
hind paws. The CAP dose was determined empirically in
pilot studies. To do this, we sought a dose that produced
robust nocifensive responses from the rats upon acute
injection (vocalization, paw shaking, paw licking, and
erythema), but did not cause subsequent analgesia when
tested with noxious thermal stimuli the next day. We
found 30 μg of CAP in 100 μl to be effective for this
purpose. The MRS1477 doses were based on our pre-
vious in vitro data, and we were primarily interested in
finding a minimum effective dose when administered
with 30 μg of CAP. Response scores (Aδ stimulus, 3.59-
5.61 W/mm2) and paw withdrawal latencies (C-fiberstimulus, 0.083 W/mm2) were evaluated prior to and at
2, 24, and 48 h following subcutaneous injection of
either MRS1477 alone, CAP alone, or the co-
administration of MRS1477 and CAP. We chose the
starting point of 2 h to minimize acute effects of the
injection on response sensitivity and also to allow time
for denervation to occur [32]. A separate cohort of rats
(n = 6) was used to compare MRS1477 alone to
untreated contralateral paws, and the behavioral data
were not found to be significantly different (not shown).
Throughout the rest of the experiments, CAP alone and
untreated contralateral paw data served as controls.
Attenuation of response sensitivity to acute thermal
stimulation was apparent as early as 2 h post-injection
(Figure 2A). The mean Aδ response score for 2 μg
MRS1477 + 30 μg CAP (1.4 ± 0.1, n = 7) was significantly
lower (p < 0.0001) than 30 μg CAP alone (2.4 ± 0.2,
n = 12), or the untreated contralateral paw (2.7 ± 0.1,
n = 19). At 2 h and a dose of 1 μg MRS1477 + 30 μg
CAP, the Aδ response score (2.3 ± 0.2, n = 12) was not
significantly different than untreated contralateral paw.
The mean C-fiber evoked paw withdrawal latency
(Figure 2B) after 2 μg MRS1477 +CAP (11.9 ± 0.4 s,
n = 7) was significantly elevated (p < 0.0001) compared to
CAP alone (9.4 ± 1.0 s, n = 12), or the untreated contral-
ateral paw (8.2 ± 0.3 s, n = 19). Withdrawal latencies after
1 μg MRS1477 +CAP (10.2 ± 0.7 s, n = 12) were signifi-
cantly higher (p < 0.01) than untreated paws (8.2 ± 0.3 s,
n = 19). Importantly, neither capsaicin alone nor
MRS1477 alone produced significant changes in
response sensitivity.
Paws treated with MRS1477+CAP showed a loss of
thermal sensitivity that persisted at 24 h (Figure 2C). The
mean Aδ response score after 2 μg MRS1477+30 μg CAP
(0.7± 0.1, n =7) was significantly lower (p <0.0001) than all
other treatments; the mean response score was 2.4±0.2
(n=12) after 1 μg MRS1477+30 μg CAP and 2.4± 0.2
(n=12) after CAP alone, which was not significantly differ-
ent from the untreated contralateral paws (2.4± 0.2, n= 19).
The mean C-fiber evoked paw withdrawal latency at 24 h
(Figure 2D) after 2 μg MRS1477+CAP (10.4± 0.6 s, n= 7)
were significantly greater (p <0.0001) than CAP alone
(7.3± 0.3 s, n =12), and compared to contralateral paws
(7.8± 0.3 s, n=19). The mean latency for 1 μg MRS1477+
CAP was significantly higher (p< 0.05) than CAP alone. At
this time, the increase in latency produced by 2 μg
MRS1477+30 μg CAP was not significantly different than
that seen with 1 μg MRS1477+30 μg CAP (8.8± 0.6 s,
n= 12).
Blunted nocifensive behavioral responses continued
for 48 h and were now apparent with tests of Aδ fibers
at both doses of MRS1477 (Figure 2E). The mean Aδ
response scores after 1 μg MRS1477 +CAP (1.8 ± 0.2,
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Figure 2 Prolonged attenuation of responses to noxious thermal stimuli following intraplantar co-administration of MRS1477 and
capsaicin. An infrared diode laser was used to preferentially stimulate Aδ- (A,C,E) or C-fibers (B,D,F,G) in the hind paw following intraplantar drug
administration. At 2 h post-injection (A,B), rats treated with 2 μg MRS1477+ 30 μg CAP showed decreased nociceptive responses to both Aδ- and
C-fiber stimuli, while rats treated with 1 μg MRS1477+ 30 μg CAP showed a significant attenuation of only C-fiber responses when compared to
untreated controls. At 24 h post-injection (C,D), rats treated with 2 μg MRS1477+ 30 μg CAP still showed decreased responses to both Aδ- and
C-fiber stimuli, and again 1 μg MRS1477+ 30 μg CAP-treated rats showed a significant increase in C-fiber withdrawal latency only. At 48 h post-
treatment (E,F), rats receiving either 1 or 2 μg MRS1477+ 30 μg CAP displayed significantly reduced nociceptive responses under both stimulus
paradigms when compared to 30 μg CAP-treated and untreated controls. Longitudinal C-fiber data are displayed for comparison (G). Since they
were not significantly different from each other, data from the untreated and 30 μg CAP-only cohorts were combined in (G). * = p< 0.5;
** = p< 0.01; *** = p< 0.001; **** = p < 0.0001.
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to CAP alone (3.2 ± 0.1, n = 12) and untreated contralat-
eral paws (2.8 ± 0.1, n = 19) (p < 0.0001). At 48 h
(Figure 2F), the mean C-fiber withdrawal latencies after
1 μg MRS1477 +CAP (9.2 ± 0.6 s, n = 12) and 2 μg
MRS1477 +CAP (10.0 ± 0.6 s, n = 7) were both signifi-
cantly greater (p < 0.01 and p < 0.0001, respectively) than
CAP alone (7.4 ± 0.6 s, n = 12), and the untreated con-
tralateral paws (7.0 ± 0.4 s, n = 19). A summary of the
dose–response effect at 2, 24, and 48 h for the C-fiber
stimuli is shown in Figure 2G. We combined CAP alone
with the untreated contralateral paw data at each time
point, since the CAP only injection had no effect. Again,
the loss of acute thermal sensitivity after 2 μg
MRS1477 +CAP is significant at all time points
(p < 0.0001), while loss of thermal sensitivity in the 1 μg
MRS1477 +CAP treatment group was significant at the
48 h test (p < 0.05). The persistent nature of the analge-
sia provided the initial indication that TRPV1-expressing
afferent nerve endings are being ablated by the com-
bined treatment.
In order to test the degree of efficacy of the PAM
treatment, we examined Aδ-evoked responses over a
range of increasing laser intensities at 24 h (Figure 3A)
and 48 h (Figure 3B) post-injection. At 24 h, Aδ
response scores were significantly attenuated at both
4.12 W/mm2 and 5.61 W/mm2 after treatment with 2 μg
MRS1477 +CAP compared to either 1 μg MRS1477 +
CAP or the controls (Figure 3A; Mann–Whitney U test,
p < 0.0001). At 48 h, Aδ response scores were recorded
at stimulus intensities ranging from 3.59–5.61 W/mm2.
Rats receiving 2 μg MRS1477 +CAP continued to show
significantly attenuated response scores at all intensities
compared to controls, while rats receiving 1 μg


















Figure 3 Paw withdrawal response as a function of Aδ stimulus inten
intraplantar drug treatment. After 24 h (A), 2 μg MRS1477+ 30 μg CAP-trea
settings compared to 30 μg CAP-only and untreated paws (p < 0.0001). Aft
significant analgesia at all power settings compared to 30 μg CAP-only and
each other, data from the untreated contralateral and 30 μg CAP-only paw
MRS1477+ 30 μg CAP (n = 12). ■30 μg CAP (n = 12). □Contralateral - No Txthe lowest laser intensities (Figure 3B; Mann–Whitney
U test).
One group of rats (n = 4) was followed longitudinally
after unilateral injection of 2 μg MRS1477 + 30 μg CAP
(Figure 4). Reduced sensitivity to both C- and Aδ-fiber
stimulation was apparent by 2 h. This attenuation peaked
between 1 and 2 days under both stimulus paradigms,
remained significantly different for at least 8 days using
the C-fiber stimulus (Figure 4A, two-way ANOVA), but
with the Aδ stimulus, sensitivity was significantly
reduced for approximately 24 days (Figure 4B, Mann–
Whitney U test). This is consistent with observations
from our previous study with RTX [8] that TRPV1-
expressing Aδ-fibers and nociceptive behaviors asso-
ciated with their activation may be more susceptible to
long term inactivation compared to C-fibers. The combi-
nation of PAM and agonist produces a long-lasting effect
similar to that of RTX, a potent vanilloid agonist.
The small diameter beam of the Aδ stimulus allowed
detailed spatial mapping of thermal sensitivity across the
plantar surface of the hind paw. All rats treated with
2 μg MRS1477 + 30 μg CAP were given a mid-plantar
injection in 100 μL total volume, and this resulted in a
pronounced loss of sensitivity in the toes (p < 0.001) and
mid-plantar (p < 0.001) area of the foot pad, but there
was no detectable effect at the heel (Figure 5, Mann–
Whitney U test). These results demonstrate that inacti-
vation occurred not only at the injection site but also on
axons running through the injection site projecting dis-
tally into the toes. These data are consistent with obser-
vations recorded after intraplantar RTX, and suggest
that axonal effects are a common feature of both PAM
and vanilloid agonist actions [8].
We have previously observed that the potent neurotoxin




















sity. Rat hind paws were stimulated at 24 and 48 h following
ted hind paws showed significant analgesia to stimuli at both power
er 48 h (B), 2 μg MRS1477+ 30 μg CAP-treated hind paws displayed
untreated controls. Since they were not significantly different from
s were combined in (B). ●2 μg MRS1477+ 30 μg CAP (n = 7). ○1 μg


















































































Figure 4 Longitudinal recovery of acute thermal pain sensation following intraplantar MRS1477+ capsaicin. Rats (n = 4) were injected
with 2 μg MRS1477+ 30 μg CAP unilaterally and were followed behaviorally for 24 days. Contralateral paws served as the untreated controls.
Sensitivity to C-fiber stimulation (A) returned more quickly (by day 14) than did sensitivity to Aδ stimulation (B). * = p< 0.05; ** = p< 0.01;
*** = p < 0.001, **** = p< 0.0001. ●2 μg MRS1477+ 30 μg CAP (n = 4). □Contralateral - No Tx (n = 4).
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http://www.molecularpain.com/content/8/1/70induced in TRPV1-expressing afferent nerve endings, pro-
duces an up-regulation of genes associated with nerve
damage and/or repair in the ipsilateral dorsal root ganglion
[8]. Therefore, we hypothesized that if MRS1477+CAP
















Figure 5 Pronounced attenuation of thermal sensitivity in mid-
plantar and distal locations after mid-plantar injection of
MRS1477+ capsaicin. Thermal sensitivity was mapped across the
plantar surface of rat hind paws with the small-diameter Aδ laser
stimulus. Withdrawal response scores were determined by subjective
scoring on a 0 to 4 scale (see Methods). Nocifensive responses were
significantly attenuated by treatment with 2 μg MRS1477+ 30 μg
CAP as compared to untreated paws in the mid-plantar region and
distally in the toes, but not in the heel. Testing was performed 48 h
after injection using a laser stimulus intensity of 4.12 W/mm2. The
beam diameter (1.6 mm) is shown to scale. ■2 μg MRS1477 + 30 μg
CAP (n = 3). □Contralateral - No Tx (n = 3).our behavioral data would correlate with increased expres-
sion of the same molecular markers in the DRG. Rats (n=3
per group) were injected unilaterally with 200 ng RTX,
30 μg CAP, 2 μg MRS1477, or 2 μg MRS1477+30 μg CAP.
The contralateral paw was not treated and DRG from this
side served as controls. After 24 h, the rats were euthanized
and the L4, L5, and L6 DRG were isolated and pooled for
each group. After extraction of total RNA, qRT-PCR was
performed to assess changes in transcript levels for several
markers (Figure 6). Expression of ATF3 (Figure 6A) was
greatly increased after treatment with either RTX
(p<0.0001) or 2 μg MRS1477+CAP (p< 0.01), while no
significant changes were seen after either CAP alone or
MRS1477 alone when compared to the controls. VIP
expression (Figure 6B) was greatly upregulated by RTX
(p<0.0001), and less so but significantly by 2 μg
MRS1477+CAP (p<0.0001), and to a lesser extent by
CAP alone (p <0.001). Although CAP induced VIP expres-
sion, the MRS1477+CAP group was significantly higher
than CAP alone (p <0.05). Both RTX (p<0.0001) and
MRS1477+CAP (p<0.05) produced a significant increase
in GAL expression compared to controls (Figure 6C), while
neither CAP alone nor MRS1477 alone produced upregula-
tion. NPY expression was also induced by RTX, CAP alone
(Figure 6D; p< 0.01), and by MRS1477+CAP (p<0.001).
RTX treatment upregulated MCP-1 (Figure 6E; p <0.05),
but CAP alone, MRS1477 alone, and MRS1477+CAP were
not different from controls.
To determine if the effect of MRS1477 on peripheral
nerve terminals was specific to TRPV1+ neurons, we
double-labeled DRG neurons via immunofluorescence
for TRPV1 and ATF3 (Figure 7). A group of rats (n = 3)
was injected with 200 ng RTX into one hind paw while
the contralateral side was left untreated. An additional
group of rats (n = 3) was injected with 30 μg CAP into
one hind paw and 2 μg MRS1477 + 30 μg CAP into the


































































































































I.    200 ng Resiniferatoxin
II.   2 µg MRS1477 + 30 µg Capsaicin
III.  30 µg Capsaicin
IV.  2 µg MRS1477
V.   Contralateral - No Treatment
Figure 6 Gene markers for axotomy are upregulated in lumbar dorsal root ganglia after intraplantar MRS1477+ capsaicin. Rats received
a hind paw injection of either 200 ng RTX, 30 μg CAP, 2 μg MRS1477, or 2 μg MRS1477 + 30 μg CAP and were compared to untreated paws.
After 24 h, whole lumbar DRG (L4-L6) were removed, RNA was isolated, and expression of ATF3 (A), VIP (B), GAL (C), NPY (D), and MCP-1 (E) was
quantified via qRT-PCR. Data were normalized to the reference gene GAPDH and then represented as the fold change relative to the untreated,
contralateral DRG. Injection of MRS1477+ CAP or RTX caused a significant upregulation of ATF3, VIP, GAL, and NPY expression compared to either
CAP-only, MRS1477-only, or untreated cohorts. Expression levels of VIP and NPY were also significantly upregulated following CAP-only treatment.
MCP-1 expression was upregulated after RTX treatment, but not after MRS1477+ CAP.
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was injected with 2 μg MRS1477 alone. After euthanasia
at 24 h, dorsal root ganglia were removed and immu-
nostained as described in the Methods. The TRPV1
antibody stained a sub-population of small- to medium-
diameter DRG cell soma (Figure 7A,B). Approximately 2
to 3 fields of TRPV1+ neurons were digitally captured
from a single ganglion at 200× magnification and used
for counting cells. ATF3 is not expressed in normal sen-
sory neurons, but after axotomy, ATF3 expression is
greatly upregulated in damaged neurons [48]. In the
untreated controls, ATF3 staining was diffuse or non-
apparent (Figure 7A,B). We found positive ATF3staining in the nuclei of TRPV1+ neurons from each
treatment group (Figure 7H), but both the
MRS1477 + CAP (Figure 7E) and the RTX (Figure 7F)
groups showed much greater TRPV1/ATF3 co-labeling
compared to CAP (Figure 7D), MRS1477 (Figure 7C), or
untreated contralateral paws (Figure 7A, p < 0.001 and
p< 0.0001, respectively; Figure 7G). In animals treated
with RTX, approximately 35% of the TRPV1+ neurons
contained ATF3+ nuclei, and in the CAP+MRS1477
group, 27% of the neurons contained ATF3+ nuclei. This
contrasts with ~3-5% of TRPV1+ neurons that coloca-
lized ATF3 in the no treatment, MRS1477 alone, and
CAP alone groups.
Figure 7 Lumbar dorsal root ganglia neurons co-label with TRPV1 and ATF3 after intraplantar MRS1477+ capsaicin. Double-
immunolabeling of TRPV1 (green) and ATF3 (red) is shown in rat DRG neurons from fixed-frozen sections (A-F). Rats were either not treated (A, B
with phase), or given an intraplantar injection of 2 μg MRS1477 (C), 30 μg CAP (D), 2 μg MRS1477+ 30 μg CAP (E), or 200 ng RTX (F). ATF3
appears as red fluorescence concentrated in neuronal nuclei. Yellow nuclei result from an overlap of ATF3+ and TRPV1+ staining. ATF3+ nuclei
were manually counted and calculated as the ratio of ATF3+/TRPV1+ cells over the total number of TRPV1+ cells in a given field (G). All treatment
groups were compared statistically to the untreated controls using an unpaired Student’s t-test (**** = p < 0.0001). Results of cell counts from 10
fields analyzed at 200× magnification are summarized (H). Arrows indicate representative co-labeled cells.
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The present data demonstrate the ability of MRS1477, a
positive allosteric modulator of TRPV1, to potentiate the
effect of capsaicin (CAP) in vivo resulting in a rapid per-
ipheral nerve terminal inactivation and a significant,
long-lasting yet reversible analgesia to cutaneous nox-
ious thermal stimulation in rats. Neither MRS1477 nor
capsaicin alone produced suppression of behavioralresponses. Evidence for loss of the cutaneous nerve
terminals was reinforced by parallel molecular studies of
gene expression changes in DRG. The corresponding
cellular specificity of the effect was examined by immu-
nohistochemical double labeling for ATF3 (a nuclear
stain) and TRPV1 (largely cytoplasmic). Intraplantar
injection of the combination of MRS1477 and CAP pro-
duced colocalization of TRPV1 and ATF3 in neurons in
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agonist-activated TRPV1 by a positive allosteric modula-
tor can produce a localized nerve terminal inactivation
in vivo that yields rapid and prolonged analgesia.
We previously demonstrated that MRS1477 exhibits
no agonist activity at TRPV1, but potentiates the cal-
cium influx induced by orthosteric vanilloid agonists
and TRPV1 stimulation by protons or sensitization by
phorbol ester [46,47]. In the previous study, we also
observed MRS1477 potentiation of intraperitoneal
capsaicin-induced hypothermia [46]. In the present
study, we were able to induce analgesia through func-
tional inactivation of peripheral primary afferent nerve
terminals similar to the long-lasting effect of the potent
TRPV1 agonist RTX, which served as our positive con-
trol [8]. Inhibition of the response to noxious thermal
stimuli was observed after administration of 2 μg
MRS1477 plus 30 μg capsaicin, while 1 μg MRS1477
plus 30 μg capsaicin produced a less robust response,
consistent with a dose-dependent relationship. Further-
more, the effect of the agonist-PAM combination was
spatially discrete. When administered as a mid-plantar
injection, the resulting analgesia occurred at the treated
area and distally in the toes with relative sparing of the
heel (see Figure 5). This localized analgesia in the mid-
plantar and distal regions suggests that the nerve term-
inal inactivation is confined to the nerve endings in the
immediate vicinity of the injection site and to axons pro-
jecting through it; an effect we have demonstrated pre-
viously with peripherally administered resiniferatoxin
[8]. We refer to the process involving nerve endings as
“nerve terminal inactivation” or “deactivation,” rather
than complete ablation, since the nerve endings can
grow back and become active again [32,55]. We also dis-
tinguish inactivation/deactivation from desensitization,
the latter referring to the progressive decrement in
response upon multiple, successive applications of a
vanilloid agonist; desensitization is an endpoint fre-
quently investigated in electrophysiological experiments.
This inactivation process can form a new potential
approach to analgesic pharmacology that is conditional
and pain-state dependent [30].
When we tracked the recovery of Aδ-mediated ther-
mal nociception, we observed substantial yet incomplete
recovery by day 4, followed by a gradual, progressive
return towards baseline over the next 20 days. With C-
fiber stimulation, there was significant attenuation of
nociceptive responses over the first 6 to 8 days and a
convergence with control latency measurements by day
14. This slow return to baseline is consistent with an
earlier study of the effects of RTX on cutaneous Aδ- and
C-fiber TRPV1-expressing nerve terminals [8]. These
data support the notion that a TRPV1 PAM, in combi-
nation with an agonist in a non-deactivating dose, canproduce a long-lasting analgesia that shares many of the
behavioral and afferent fiber-type specific characteristics
obtained by treatment with the potent, selective agonist
RTX.
Gene upregulation of markers for neuronal damage in
dorsal root ganglia also provides evidence that PAM
treatment modifies the integrity of primary afferent
nerve terminals. This was explored using two
approaches: transcript amplification by qRT-PCR and
immunohistochemical staining for relevant proteins and
neuropeptides. Increased transcript levels of nerve
damage biomarkers were measured in the dorsal root
ganglia for the transcription factor ATF3 [48] and the
neuropeptides vasoactive intestinal peptide (VIP) [51-
53], galanin (GAL) [50], and neuropeptide Y (NPY) [49].
We previously demonstrated that these molecules can
also be induced by injection of RTX into the hind paw; a
result consistent with chemo-axotomy of the TRPV1-
expressing nerve endings. By extension, we hypothesized
that the PAM/agonist combination would produce a
similar effect. Our qRT-PCR data demonstrated that
MRS1477 plus CAP resulted in an induction of ATF3,
VIP, NPY, and GAL transcripts. In contrast, neither CAP
nor MRS1477 alone induced upregulation of any of the
biomarkers except NPY and VIP, which were upregu-
lated after CAP alone. This may be related to the low
but detectable basal expression levels of NPY compared
to the other genes, which are nearly undetectable at
basal state. For VIP, while induction by CAP is higher
than in the untreated contralateral DRG, treatment with
MRS1477 +CAP produces both significantly greater VIP
induction and behavioral effects compared to CAP
alone.
We determined that the molecular axotomy was speci-
fic to TRPV1+ neurons by immunofluorescence double
labeling using antibodies targeting TRPV1 and ATF3.
Both the behavioral and molecular data suggest that
MRS1477 is working on TRPV1-expressing afferent
terminals. We reasoned that this could be further sub-
stantiated if the elevation in ATF3 was enriched in
TRPV1-expressing neurons in the DRG. Figure 7 shows
that in rats treated with MRS1477 and CAP, nuclear
staining for ATF3 is found predominantly in TRPV1
expressing neurons: 93% (82/88) of ATF3 positive nuclei
co-localized to TRPV1-stained neurons, and this percen-
tage is similar following positive control injections of
RTX (79%, 100/126). However not all TRPV1+ neurons
expressed ATF3. Likely, these represent TRPV1+ neu-
rons with axons terminating in the lower limb but not in
the treated plantar surface of the hind paw. Extensive
co-localization of axotomy-related molecular alterations
to TRPV1+ neurons suggests a high degree of cellular
specificity for MRS1477. At the same time, the rats did
not exhibit autotomy behaviors that commonly
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results are consistent with earlier studies on peripheral
injections of RTX into the hind paw [32], perineurally
[38,55], or directly into rat or monkey trigeminal [33,59].
These data suggest that our TRPV1 PAM is producing
the expected on-target effects and does not produce
unexpected sensory abnormalities.
Evidence from this experiment and our previous RTX
studies [8,32] suggest that TRPV1-expressing Aδ-fibers
are more susceptible to long-term denervation. The
greater structural complexity of lightly myelinated Aδ-
fibers could account for the apparent disparity in func-
tional recovery time compared to unmyelinated C-fibers
[60]. Also, the paranodal location of the plasma-
membrane calcium ATPase [61], a major regulator of
intracellular calcium levels in myelinated DRG neurons
[62,63], may accentuate calcium toxicity in Aδ-fibers. It
is interesting to speculate whether differential efficacy at
the two fiber types could form a useful strategy for treat-
ing pathological pain problems.
Allosteric modulation is an important approach to
consider in therapeutic drug development [64]. Cur-
rently, allosteric modulation of GABAA ligand-gated ion
channels is a well-exploited mechanism for general anes-
thetics, benzodiazepine pre-anesthetic medications, and
anxiolytics [65-67]. Agonist potentiation is also being
explored to mitigate the side effects of poorly tolerated
but otherwise effective analgesics acting on, for example,
GABAB receptors [68] and nicotinic acetylcholine recep-
tors [69]. Conversely, negative allosteric modulation of
glutamate receptors has been explored clinically for the
treatment of migraine [70]. Our studies investigate
MRS1477 as a proof-of-concept molecule for allosteric
potentiation of TRPV1. We have demonstrated that
MRS1477 can effectively modulate CAP activation
in vitro and in vivo, and while CAP is not a physiologi-
cally relevant agonist, our model serves as a framework
for future testing of animal pain models. In pathological
states there are several variables that can influence PAM
efficacy. TRPV1 PAM actions are predicated on the exis-
tence and generation of endogenous TRPV1 activators
(endovanilloids) that are adequately potent and present
in sufficient concentrations at sites of tissue damage or
inflammation to bind to the orthosteric vanilloid site;
low pH also plays an activating role [71,72]. A model for
the interactions between TRPV1, PAMs, and endovanil-
loids is presented in Figure 1, which shows a diagram of
four potential states of the receptor: closed, both sites
unoccupied; closed with PAM site occupied; open with
vanilloid site occupied; and open with both sites occu-
pied. It may be that only certain pain conditions gener-
ate sufficient endovanilloids or protons to be permissive
for positive allosteric modulation of TRPV1. In chronic
pain states, nociceptive nerve endings remain active anddo not transition into an inactive state without pharma-
cological intervention, since the endings have multiple
mechanisms to cope with transmembrane calcium flux
[62]. Thus, despite a low pH and an endovanilloid-
enriched environment, the added “push” from a PAM
would be necessary to achieve nerve terminal inactiva-
tion [46].
Perhaps the greatest advantage of a TRPV1 PAM in
terms of clinical pharmacology is the mechanism of
calcium-mediated nerve terminal inactivation, which can
potentially produce an effective, long-term analgesia.
Even the most highly specific TRPV1 antagonist blocks
just one ligand-gated ion channel, leaving numerous
other TRPV1-independent receptors on the nerve end-
ings available for stimulation by algesic mediators. In
contrast, nerve terminal inactivation renders the fiber
essentially insensitive to a variety of noxious stimuli.
Thus, several practical and theoretical characteristics of
a TRPV1 PAM offer the potential for a new, emerging
class of analgesics.
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